2-(3-amino-4-methoxyphenyl)-benzoxazole | 378222-48-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(3-amino-4-methoxyphenyl)-benzoxazole
• 英文别名: 2-(3-amino-4-methoxyphenyl)benzoxazole；5-(1,3-Benzoxazol-2-yl)-2-methoxyaniline
• CAS: 378222-48-1
• 化学式: C₁₄H₁₂N₂O₂
• mdl: MFCD00298038
• 分子量: 240.261
• InChiKey: AKUUHWRDNLCHCT-UHFFFAOYSA-N

物化性质

• 沸点：
  396.8±32.0 °C(Predicted)
• 密度：
  1.257±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  61.3
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  N,N-二甲基甲酰胺二甲基缩醛 、 2-(3-amino-4-methoxyphenyl)-benzoxazole 在 sodium tetrahydroborate 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 1.0h， 以47%的产率得到2-(3-N-methylamino-4-methoxyphenyl)benzoxazole
  参考文献：
  名称：

  [EN] SUBSTITUTED PHENYLUREA DERIVATIVES AS HDAC INHIBITORS
  [FR] DERIVES DE PHENYLUREE SUBSTITUES EN TANT QU'INHIBITEURS D'HDAC

  摘要：

  公开号：

  WO2004067480A3
• 作为产物：
  描述：

  4-甲氧基-3-硝基苯甲酸 在 palladium on activated charcoal 草酰氯 、 氢气 、 对甲苯磺酸 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 乙酸乙酯 、 甲苯 为溶剂， 生成 2-(3-amino-4-methoxyphenyl)-benzoxazole
  参考文献：
  名称：

  2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors

  摘要：

  A novel class of 2,3-dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acids are described as inhibitors of the endo-beta-glucuronidase heparanase. Several of the compounds, for example, 2-[4-propylamino-5-[5-(4-chloro)phenyl-benzoxazol-2-yl]phenyl]-2,3-dihydro-1,3-dioxo-IH-isoindole-5-carboxylic acid (9c), display potent heparanase inhibitory activity (IC50 200-500nM) and have high selectivity ( > 100-fold) over human beta-glucuronidase. They also show anti-angiogenic effects. Such compounds should serve as useful biological tools and may provide a basis for the design of novel therapeutic agents. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.086

文献信息

• [EN] PHTHALIMIDE CARBOXYLIC ACID DERIVATIVES<br/>[FR] DERIVES D'ACIDES CARBOXYLIQUES PHTALIMIDIQUES
  申请人：OXFORD GLYCOSCIENCES UK LTD

  公开号：WO2003074516A1

  公开（公告）日：2003-09-12

  The present invention relates to phthalimide carboxylic acid derivatives of formula (I), methods for their preparation, pharmaceutical compositions containing them and their use in medicine, specifically in the treatment of cancer. (I), wherein X is O or S; R1 is a phthalimide carboxylic acid group of formula (II). R is hydrogen, C1-C6 alkyl, aryl or C1-C3 alkylaryl and R2, R3 and R4 represent various substituents.

  本发明涉及公式（I）的邻苯二甲酰亚胺羧酸衍生物，其制备方法，含有它们的药物组合物以及它们在医学中的应用，具体用于癌症治疗。在公式（I）中，X为O或S；R1为公式（II）的邻苯二甲酰亚胺羧酸基团。R为氢、C1-C6烷基、芳基或C1-C3烷基芳基，R2、R3和R4代表各种取代基。
• Phthalimide carboxylic acid derivatives
  申请人：Courtney Martin Stephen

  公开号：US20050203153A1

  公开（公告）日：2005-09-15

  The present invention relates to phthalimide carboxylic acid derivatives of formula (I), methods for their preparation, pharmaceutical compositions containing them and their use in medicine, specifically in the treatment of cancer. (I), wherein X is O or S; R 1 is a phthalimide carboxylic acid group of formula (II). R is hydrogen, C 1 -C 6 alkyl, aryl or C 1 -C 3 alkylaryl and R 2 , R 3 and R 4 represent various substituents.

  本发明涉及公式（I）的邻苯二甲酰亚胺羧酸衍生物，其制备方法，包含它们的制药组合物以及它们在医学上的用途，特别是在癌症治疗中。其中，X为O或S；R1是公式（II）的邻苯二甲酰亚胺羧酸基团。R为氢，C1-C6烷基，芳基或C1-C3烷基芳基，而R2，R3和R4代表各种取代基。
• TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
  申请人：Wynne Graham Michael

  公开号：US20090075938A1

  公开（公告）日：2009-03-19

  There are disclosed compound of Formula (1): A 1 , A 2 , A 3 and A 4 which may be the same or different, represent N or CR 1 , X is a divalent group selected from O, S(O) n , C═W, NR 4 , NC(═O)R 5 and CR 6 R 7 , W is O, S, NR 20 , Y is N or CR 8 , one of R 4 , R 5 , R 6 , R 8 , R 9 and NR 20 represents -L-R 3 , in which L is a single bond or a linker group, additionally, R 1 , R 3 -R 9 , which may be the same or different, independently represent hydrogen or a substituent and R 20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO 2 , NR 30 R 31 , in which R 30 and R 31 , which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R 30 and R 31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A 1 -A 4 each represent CR 1 , then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR 6 R 7 , R 6 and R 7 , together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.

  公式（1）的化合物被揭示：A1，A2，A3和A4，它们可以相同或不同，代表N或CR1，X是从O，S（O）n，C═W，NR4，NC（═O）R5和CR6R7中选择的二价基团，W是O，S，NR20，Y是N或CR8，R4，R5，R6，R8，R9和NR20中的一个表示-L-R3，在其中L是单键或连接基团，此外，R1，R3-R9可以相同或不同，独立地表示氢或取代基，R20表示氢，羟基，可以用芳基取代的烷基，可以用芳基取代的烷氧基，芳基，CN，可以用芳基取代的烷氧基，可以用芳基取代的芳氧基，可以用取代基取代的烷酰基，可以用取代基取代的芳酰基，NO2，NR30R31，在其中R30和R31可以相同或不同，表示氢，可选地取代的烷基或可选地取代的芳基；此外，R30和R31中的一个可以表示可选地取代的烷酰基或可选地取代的芳酰基，n表示从0到2的整数，另外，当相邻的A1-A4中的一对表示CR1时，那么相邻的碳原子及其取代基可以形成环B，当X为CR6R7时，R6和R7与它们附着的碳原子一起可以形成环C，或其药学上可接受的盐，在制造用于治疗和/或预防杜氏肌萎缩症，贝克肌萎缩症或消瘦症的药物时使用。
• Indazole compounds
  申请人：Ericsson M. Anna

  公开号：US20070282101A1

  公开（公告）日：2007-12-06

  Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  本发明提供了化合物(I)或其药学上可接受的盐、前药和生物活性代谢物，其中取代基如定义所述，这些化合物可用作治疗剂。
• Indazole Compounds
  申请人：Ericson Anna M.

  公开号：US20120053345A1

  公开（公告）日：2012-03-01

  Novel compounds of Formula (I) or pharmaceutically acceptable salts, prodrugs and biologically active metabolites thereof of Formula (I) wherein the substituents are as defined herein, which are useful as therapeutic agents.

  本发明涉及化合物(I)或其药学上可接受的盐、前药和生物活性代谢物，其中取代基的定义如本文所述，这些化合物可用作治疗剂。